Dominant negative MYC blocks transformation by ABL oncogenes.
about
BIN1 is a novel MYC-interacting protein with features of a tumour suppressorDirect interaction of Jak1 and v-Abl is required for v-Abl-induced activation of STATs and proliferationThe Myc target gene JPO1/CDCA7 is frequently overexpressed in human tumors and has limited transforming activity in vivoTLS/FUS, a pro-oncogene involved in multiple chromosomal translocations, is a novel regulator of BCR/ABL-mediated leukemogenesis.Tyrosine phosphorylation of p95Vav in myeloid cells is regulated by GM-CSF, IL-3 and steel factor and is constitutively increased by p210BCR/ABLGadd45 stress sensors in malignancy and leukemiaEnhanced phosphorylation of Nbs1, a member of DNA repair/checkpoint complex Mre11-RAD50-Nbs1, can be targeted to increase the efficacy of imatinib mesylate against BCR/ABL-positive leukemia cellsKnockdown of c-Myc expression by RNAi inhibits MCF-7 breast tumor cells growth in vitro and in vivo.Chronic myeloid leukemia: reminiscences and dreamsNovel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571.Transforming pathways activated by the v-Abl tyrosine kinaseModeling of molecular interaction between apoptin, BCR-Abl and CrkL--an alternative approach to conventional rational drug designThe cytostatic function of c-Abl is controlled by multiple nuclear localization signals and requires the p53 and Rb tumor suppressor gene productsActivation of cyclin-dependent kinases by Myc mediates induction of cyclin A, but not apoptosisProgressive changes in the leukemogenic signaling in BCR/ABL-transformed cells.Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesisStructural requirements for function of the Crkl adapter protein in fibroblasts and hematopoietic cells.Deletion of the ABL SH3 domain reactivates de-oligomerized BCR-ABL for growth factor independence.En bloc substitution of the Src homology region 2 domain activates the transforming potential of the c-Abl protein tyrosine kinase.Signaling pathways activated by oncogenic forms of Abl tyrosine kinase.New Myc-interacting proteins: a second Myc network emerges.Mechanisms of apoptosis by c-Myc.Selecting the best frontline treatment in chronic myeloid leukemiaDisruption of the Shc/Grb2 complex during abelson virus transformation affects proliferation, but not apoptosis.MYC Deregulation in Primary Human Cancers.Temperature-sensitive transformation by an Abelson virus mutant encoding an altered SH2 domain.Signaling by ABL oncogenes through cyclin D1.Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia.The role of STATs in myeloid differentiation and leukemia.JAK-STAT signaling activated by Abl oncogenes.Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis.c-Myc target genes involved in cell growth, apoptosis, and metabolismp53 mediates apoptotic crisis in primary Abelson virus-transformed pre-B cells.The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and Raf.Protein-protein interactions: methods for detection and analysisCRTC1/MAML2 gain-of-function interactions with MYC create a gene signature predictive of cancers with CREB-MYC involvement.Rescue of defective mitogenic signaling by D-type cyclins.Regulation of hTERT by BCR-ABL at multiple levels in K562 cells.Jak2 is involved in c-Myc induction by Bcr-Abl.Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2.
P2860
Q24318855-218BFA33-4332-414C-8206-91CF70F76896Q24522820-699849F4-211B-4DE2-9118-CDF79B7B38F7Q24531376-28AF646F-251D-4BA5-A525-BE28678A1C6AQ24533281-E0BA70FB-8DCB-47BE-9EF5-0B6253A9FB6FQ24568367-0BB2ADB8-9835-41B8-9ABC-3B33210AEECFQ24600698-58413BD8-5302-4DB3-9DD5-E781EA7B2877Q24670609-CBDB9396-186D-4D88-BBE6-534293E085B1Q24797399-9C8D01B8-1521-43DF-86F5-4BCDE8109A7FQ26748769-86307B8A-3F5A-43BD-9EEF-3061D4BBA4C6Q27824789-11FA9001-A9BA-41B2-8AFE-423CF8A426CBQ28217156-B1454B4E-76FA-43EF-9753-4D847319904DQ28478748-DE9AB127-D4EE-46DA-B738-FB7FAA5384ADQ28508496-7679ED38-C954-482E-97D2-E7A866D42579Q28775677-90266C2A-8B12-476D-803D-C99D98FB00C8Q30168802-436714FD-2072-4B8C-96C2-2CBD19579595Q30175784-FA3D01C0-65FE-48B6-8209-41400FCF4FD6Q30176087-FB9FC195-2EBC-4B67-84D5-F1945F0FAD7CQ30192639-FF83863D-9A90-4870-B928-D8823A0EBA4CQ30195067-0AFB7232-D752-4846-BE0E-EB414BFC2D2FQ33663180-187DFEF8-B0E3-4DFE-84AF-F5B6D057549FQ33667300-4AED6EAB-2B7B-4CF2-9D21-AC7F008FE819Q33667315-C947FE75-FB81-4B87-89EA-788E204D8A7AQ33764253-0C737721-AD9B-45DD-B0ED-23B52D5D7D8EQ33782337-7BC4F754-945C-44B6-BDED-913F7DCB0E15Q33836755-202FD8B9-08C9-4AC9-97F2-B5DE93F8CB0DQ33837688-F344D6AA-4BA4-4B83-A568-10FCAAA589BAQ33852649-5E0DF0E5-745D-480B-AC85-D776CB16D843Q33903030-C279E51A-2292-46C4-88EF-AADD39824428Q33941366-8A5A1F3C-4599-4832-B649-B69EFCECCFB5Q33941370-E93D514B-166E-456B-8E2E-3147F1B8145BQ33951212-FC061F36-5017-4948-B247-CE81B100B203Q33956988-3270E0A8-9584-487C-B6FD-80F957F35C72Q33958575-8A1A9367-168A-4CF6-B23F-9BFA37C81365Q33961839-BA64069B-1FAF-48E9-9BE0-798943656AD7Q34058635-67178AB3-84F4-4685-BA90-D89A13E3B016Q34060539-5BEAA592-9F20-4B57-B58C-346BD022A690Q34080582-56BCA52A-5770-4593-B847-3D254E84FC42Q34094028-486C1538-6E34-4BC9-9026-AA0845473743Q34153616-F9A1094A-5879-44FC-AF13-538709ACA09DQ34206916-105AA74C-A692-4F57-A9A0-45C3674E5698
P2860
Dominant negative MYC blocks transformation by ABL oncogenes.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh-hant
name
Dominant negative MYC blocks transformation by ABL oncogenes.
@en
Dominant negative MYC blocks transformation by ABL oncogenes.
@nl
type
label
Dominant negative MYC blocks transformation by ABL oncogenes.
@en
Dominant negative MYC blocks transformation by ABL oncogenes.
@nl
prefLabel
Dominant negative MYC blocks transformation by ABL oncogenes.
@en
Dominant negative MYC blocks transformation by ABL oncogenes.
@nl
P2093
P1433
P1476
Dominant negative MYC blocks transformation by ABL oncogenes.
@en
P2093
P304
P356
10.1016/0092-8674(92)90241-4
P407
P577
1992-09-01T00:00:00Z